Pharma Consulting & Analytics

Evaluate offers a pharmaceutical consulting & analytics service designed to help clients address unique scientific, clinical and commercial challenges

We combine our robust and comprehensive clinical and commercial data, advanced, yet flexible analytical models, pharma intelligence machine learning tools, expertise, and strategic frameworks to address our clients’ specific challenges and business needs.

Since our inception, we have delivered projects in asset screening, benchmarking, asset and portfolio valuation, partner search and screen, competitive landscape and ROI assessment for over 100 clients across the pharmaceutical and biotech ecosystems globally.

Our services

OUR SERVICES

Our Pharmaceutical Consulting & Analytics services are designed for teams defining product and portfolio strategies and setting direction for key brands and franchises. Our pharmaceutical consulting services provide insight into: 

  • Market Analysis & Competitor Intelligence
  • Corporate Strategy & Franchise Planning
  • Market Expansion & Forecasting
  • Mergers & Acquisition
  • New Product Development
  • Market Access and Pricing
  • Commercialization
our services infographic

Leveraging a foundation of extensive Evaluate data, augmented with further secondary research, modeling and analysis, our pharmaceutical consulting solutions are data-driven and insight-focused. We also conduct targeted primary research with Key Opinion Leaders, Healthcare Professionals and Payers to validate our assumptions and test our hypotheses.

Below we have provided an overview of our pharma data analytics and consulting services and how they apply to various business challenges or opportunities. If there is something that is not listed here please contact us so we can work with you to get you the insights and recommendations you need.

infographic pyramid

OUR CLIENTS

Our clients range from startups to major players, consultancies, investors, industry suppliers and banks. Our clients use our Pharmaceutical Consulting and Data Analytics services to gain gain insight into the following critical questions

CORPORATE AND PORTFOLIO LEVEL
  • Which Therapeutic Areas present the greatest commercial opportunities and which sub-populations have the greatest unmet needs?
  • Which geographies and indications hold the greatest potential?
  • How can we optimize the value of our existing portfolio – what are key industry trends and growth drivers that could impact the portfolio?
  • What is the competitive landscape and outlook?
ASSET LEVEL
  • Which Therapeutic Areas present the greatest commercial opportunities and which sub-populations have the greatest unmet needs?
  • Which geographies and indications hold the greatest potential?
  • How can we optimize the value of our existing portfolio – what are key industry trends and growth drivers that could impact the portfolio?
  • What is the competitive landscape and outlook?

If you’d like to find out more about how we can support you with our pharma intelligence solutions, please get in touch with our Client Engagement team.

READ CASE STUDIES

OUR TEAM

We have a global team of 25 people on the ground in the key pharma and biotech markets of the US, Europe, and Japan. With advanced degrees / PhDs in areas including Molecular Medicine, Biomedical Science, Natural Sciences, Genetics, Neuroscience, Clinical Pharmacology, Data Science and Machine Learning, our team has over 140 years combined biotech and pharma analytics experience. If you’d like to find out more about our pharma data analytics and consulting services, please get in touch with our Client Engagement team

MEET THE TEAM
Our team

I really could not do my job without Evaluate data. You guys make me look good all the time.

Business Development & Licensing, Large Pharmaceutical

Evaluate makes it possible for us to assess the commercial value for different products, as well as understand the major trends in the pharmaceutical industry. It gives us the ability to calculate the share of company sales that are coming from organic or externally sourced products, and understand how companies are investing.

Dr. Hirohisa Nakada, Associate Director, Business Development Department, Otsuka Holdings

OUR WORK & CASE STUDIES

 

We have worked with the world’s largest Pharmaceutical companies including Abbvie, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Gilead, GSK, Johnson & Johnson/Janssen, Merck KGaA, Novartis, Pfizer, Roche/Chugai and Sanofi.

main icon
Corporate Strategy Teams

An external industry perspective to complement your views on the market, competition, and your company's strategic direction.

Find out how a major global pharma gained an external perspective on market trends to support a key Executive Team strategy session.

goal
Commercial Operations, Pricing & Forecasting

Customized epidemiology research, forecast modelling, and pricing analysis to inform your product strategy and tactical planning.

Find out how a pharma commercial and finance group established a standard forecasting methodology across an entire business.

cog
Business Development & Licensing

Expedite your search and screen efforts and access robust, data-driven analysis to support opportunity assessment.

Find out how a mid-sized pharma BD&L team outsourced their search and screen efforts for a shortlist of assets with potential for licensing.

GET IN TOUCH

Get in touch
Get in touch
MULTI DISCPLINED EXPERTS IN FORECASTS.
MULTI DISCIPLINED EXPERTS IN FORECASTS

Our unmatched combination of industry renowned forecasts, proprietary methodologies and ubiquitous products along with our highly qualified, multi-disciplined experts; uniquely positions us as the only choice when you need cost-effective, deeply analytical, data-driven insight.  Please download to find out more.

RARE DISEASE PREVELANCE
RARE DISEASE PREVALENCE

Largely driven by the payer environment, the focus of drug development has shifted in the last 10 years to rare diseases.  Due to the lack of solid epidemiology data available, over 7,000 rare diseases (many being sub-sets of larger diseases), have not been quantified, posing a problem when using prevalent population estimates to create forecasts.  This document discusses the challenges in determining accurate patient population estimates for rare diseases and the best practice methodologies to arrive at appropriate prevalent and incident population figures.

asset valuation
ASSET VALUATION

Healthcare is a heavily specialist arena and it is not always easy to understand what a quality valuation should be based on and include.  Accurate consideration of true drivers of the market is both an art and a science.  This document breaks the valuation down in to its constituent income and expenditure parts and discusses the level of detail that is expected.